This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


Novartis AG

Drug Names(s): Atriance (EU), 506U78

Description: Arranon, a novel water soluble prodrug of ara-G with T- cell selectivity, was discovered by GlaxoSmithKline. It is a nucleoside analogue that is rapidly converted to its corresponding arabinosylguanine nucleotide triphosphate (araGTP), resulting in inhibition of DNA synthesis and cytotoxity. Pre-clinical studies suggest that T-cells are particularly sensitive to Arranon and early clinical work shows promising activity in aggressive T-cell malignancies.

Arranon is approved for the treatment of patients with T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) whose disease has not responded to or has relapsed following treatment with at least two chemotherapy regimens.

Deal Structure: GlaxoSmithKline and Novartis
In April 2014, GSK and Novartis entered into a sale agreement under which GSK has agreed to sell, upon completion of the Transaction, the rights to GSKs currently marketed oncology portfolio, related R&D activities and its AKT inhibitor currently in development as well as to grant Novartis preferred partner rights for future commercialisation of GSK oncology products for an aggregate cash consideration of $16 billion. Up to $1.5 billion of this cash consideration depends on the results of the COMBI-d trial, a Phase III study evaluating the safety and efficacy of the combination of Tafinlar (BRAF) and Mekinist (MEK) versus BRAF monotherapy in patients with unresectable or metastatic melanoma.

GSK's marketed Oncology portfolio comprises the rights to GSK's currently marketed oncology assets (Votrient, Arzerra, Promacta/Revolade, Tykerb/Tyverb, Tafinlar, Mekinist, Arranon, Hycamtin, Zofran, Argatroban and Alkeran). Also being sold to...See full deal structure in Biomedtracker

Arranon News

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug